{"id":13886,"date":"2021-02-02T09:17:06","date_gmt":"2021-02-02T09:17:06","guid":{"rendered":"https:\/\/clinlabint.com\/?p=13886"},"modified":"2021-02-02T16:00:58","modified_gmt":"2021-02-02T16:00:58","slug":"erba-mannheim-launches-2nd-generation-sars-cov-2-rt-pcr-assay-with-room-temperature-storage","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/erba-mannheim-launches-2nd-generation-sars-cov-2-rt-pcr-assay-with-room-temperature-storage\/","title":{"rendered":"ERBA Mannheim launches 2nd generation SARS-CoV-2 RT-PCR Assay with room temperature storage"},"content":{"rendered":"

\"Erba<\/p>\n

In response to the ongoing COVID-19 pandemic, Erba Mannheim has launched the ErbaMDx SARS-CoV-2 RT-PCR Kit for detection of SARS-CoV-2.<\/p>\n

To overcome challenges in older COVID-19 molecular tests, Erba\u2019s Cambridge(UK)-based development team has engineered a new assay to improve detection and ease of use with a single tube multiplex mastermix, compatible with room-temperature storage and transportation.<\/p>\n

The new assay offers 200 copies\/ml LoD, using universally trusted gene targets highly specific for SARS-CoV-2 and updated primer sequences to maximise long term performance. Sample types include both nasopharyngeal and oropharyngeal swabs as well as saliva.<\/p>\n

Nikhil Vazirani, MD of Erba, said: \u201cWe are proud and excited to add a highly sensitive RT-PCR test to our growing range of immunoassay and molecular solutions. The new ErbaMDx SARS-CoV-2 test perfectly complements our successful COVID-19 IgG and IgM ELISA assays to offer customers a state-of-the-art molecular test in addition to antibody testing which will offer clinicians valuable insight into the immune response to infection or vaccination.\u201d<\/p>\n

The CE-marked kit will be available through Erba\u2019s global distribution network.<\/p>\n

Erba Mannheim, established in over 100 countries, focusses on delivering innovative, affordable and sustainable diagnostic solutions to labs everywhere. The Erba group uses a combination of cutting-edge R&D in 4 continents with efficient low-cost manufacturing to make diagnostic technologies accessible in all resource settings.<\/p>\n